Progressive supranuclear palsy (PSP) is a rare and progressive neurodegenerative disorder for which there is currently no cure. However, there are ongoing clinical trials investigating potential treatments for PSP. These trials aim to evaluate the safety and effectiveness of various drugs and therapies in reducing the symptoms of PSP and slowing its progression.
Some of the drugs that are being studied in clinical trials for PSP include:
Tau protein inhibitors: PSP is characterized by the accumulation of abnormal tau protein in the brain. Tau protein inhibitors are drugs that target the tau protein and aim to reduce its accumulation. Some examples of tau protein inhibitors being studied in PSP trials include LMTX, TPI-287, and RO7105705.
Anti-inflammatory drugs: Inflammation in the brain may contribute to the progression of PSP. Anti-inflammatory drugs, such as pioglitazone and dextromethorphan, are being investigated in clinical trials to see if they can reduce inflammation and slow down the progression of PSP.
Glutamate modulators: Glutamate is a neurotransmitter that is involved in many brain functions, including learning and memory. However, excessive glutamate release can be toxic to brain cells, and may contribute to neurodegeneration in PSP. Glutamate modulators, such as riluzole and memantine, are being studied to see if they can reduce glutamate toxicity and improve symptoms in PSP patients.
Stem cell therapy: Stem cells have the ability to differentiate into various types of cells, and may be able to repair damaged brain tissue in PSP. Clinical trials are underway to investigate the safety and effectiveness of stem cell therapy in treating PSP.
It is important to note that clinical trials for PSP are still in the early stages, and more research is needed to determine the safety and effectiveness of these treatments. If you or a loved one is interested in participating in a clinical trial for PSP, you should talk to your doctor and research clinical trials in your area.